Sirolimus (rapamycin), everolimus, and temsirolimus have been approved by the FDA for the treatment of HER2-negative breast cancer, pancreatic neuroendocrine tumors, renal cell carcinomas, or angiomyolipomas. Here, ERBB2 is linked to hereditary clear cell renal cell carcinoma.